Randomized trial to assess bone mineral density (BMD) effects of zoledronic acid (ZA) in postmenopausal women (PmW) with breast cancer

被引：0
|
作者：
Tevaarwerk, A.
Stewart, J. A.
Love, R.
Binkley, N. C.
Black, S.
Eickhoff, J.
Mulkerin, D. L.
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] Ohio State Univ, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19558
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The effect of zoledronic acid on bone mineral density and bone turnover in patients with early breast cancer on the AZURE trial
    Shankland, C.
    Coleman, R.
    BREAST, 2011, 20 : S71 - S71
  • [22] Effect of zoledronic acid (ZA) versus placebo on bone mineral density (BMD) in androgen-deprived prostate cancer patients with and without bone metastases (mets).
    Ryan, CW
    Huo, D
    Hanson, M
    Stadler, WM
    Vogelzang, NJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 446S - 446S
  • [23] Bone mineral density and bone turnover in postmenopausal women treated for breast cancer
    Waltman, Nancy L.
    Ott, Carol D.
    Twiss, Janice J.
    Gross, Gloria J.
    Lindsey, Ada M.
    Moore, Timothy E.
    CANCER NURSING, 2008, 31 (03) : 182 - 190
  • [24] EFFECTS OF ZOLEDRONIC ACID ON BONE MINERAL DENSITY IN MOROCCAN PATIENTS WITH OSTEOPOROSIS TREATED FOR BREAST CANCER
    Assadi, R.
    Nassar, K.
    Janani, S.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S340 - S341
  • [25] The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)
    Schenk, N.
    Lombart, A.
    Frassoladti, A.
    Neven, P.
    Jerusalem, G.
    Deleu, I.
    Mebis, J.
    Maerevoet, M.
    Miller, J.
    Dias, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 186 - 187
  • [26] Changes in bone mineral density (BMD) of postmenopausal women who are not receiving adjuvant endocrine therapy for breast cancer (BCA)
    Van Poznak, C.
    Morris, P. G.
    D'Andrea, G.
    Schott, A.
    Griggs, J.
    Fornier, M.
    Smerage, J.
    Henry, L.
    Collins, T.
    Hurria, A.
    Drullinsky, P.
    Mills, N. E.
    Hayes, D. F.
    Hudis, C.
    BONE, 2010, 47 : S308 - S308
  • [27] Characteristics of bone mineral density in Korean postmenopausal breast cancer women
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 70 - 70
  • [28] Anastrozole use does not appear to change bone mineral density (BMD) or bone turnover markers in postmenopausal Japanese women with breast cancer
    Reactions Weekly, 2006, 1122 (1) : 5 - 5
  • [29] Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
    McClung, Michael
    Miller, Paul
    Recknor, Chris
    Mesenbrink, Peter
    Bucci-Rechtweg, Christina
    Benhamou, Claude-Laurent
    OBSTETRICS AND GYNECOLOGY, 2009, 114 (05): : 999 - 1007
  • [30] EFFECT OF ZOLEDRONIC ACID COMPARED TO RALOXIFENE ON BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY
    Simon, James A.
    Bachmann, Gloria
    Warren, Michelle
    Kemp, Charisse
    Kianifard, Farid
    Goncalves, Joana
    Kriegman, Audrey
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S204 - S205
12345